CHMP vouches for Ascendis Pharma's growth hormone for children
![Photo: Kevin Grønnemann](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article11298514.ece/ALTERNATES/schema-16_9/ascendis.jpg)
Children and adolescents aged 3 to 18 years old with growth hormone deficiency (GHD) should be able receive treatment with Ascendis Pharma's growth hormone Skytrofa, says the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Ascendis launches growth hormone Skytrofa in the US
For subscribers